SCHEMBL12437347

SCHEMBL12437347

CC(C)C(C(=O)N1CCC(Oc2ccc(C(=O)NCCCN3CCCC3)cc2Cl)CC1)c1ccc(Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC5A7 Q9GZV3 1/20 0.51
LMNA P02545 1/20 0.48
F10 P00742 1/20 0.47
HRH3 Q9Y5N1 2/20 0.47
RAB9A P51151 1/20 0.46
SMYD2 Q9NRG4 1/20 0.46
CACNA1G O43497 4/20 0.45
ALDH1A1 P00352 1/20 0.45
L3MBTL3 Q96JM7 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HTR3A P46098 1/20 0.43
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13925104 0.87 SLC5A7 (0.52) SLC5A7LMNAF10HRH3RAB9A
SCHEMBL12437345 0.84 SMYD2 (0.51) SLC5A7HRH3RAB9ASMYD2L3MBTL3
SCHEMBL12437776 0.83 SMYD2 (0.49) SLC5A7LMNAF10HRH3RAB9A
SCHEMBL12437349 0.81 SLC5A7 (0.53) SLC5A7LMNAF10HRH3RAB9A
SCHEMBL12437331 0.80 SLC5A7 (0.54) SLC5A7LMNAF10HRH3SMYD2
SCHEMBL12437354 0.79 DRD2 (0.56) SLC5A7HRH3SMYD2DRD2DRD3
SCHEMBL12437957 0.79 SLC5A7 (0.51) SLC5A7F10SMYD2ALDH1A1MEN1
SCHEMBL13158844 0.78 F10 (0.49) SLC5A7LMNAF10SMYD2CACNA1G
SCHEMBL12437332 0.78 UTS2R (0.55) SLC5A7LMNASMYD2ALDH1A1MEN1
SCHEMBL12437352 0.77 SLC5A7 (0.49) SLC5A7LMNAF10HRH3SMYD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 US disclosed
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof HPGDS, HPGD, DPYD SLC5A7 4329/4885LMNA 2809/4885F10 4167/4885
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof HPGDS, HPGD, DPYD SLC5A7 4329/4885LMNA 2809/4885F10 4167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.